# CM336-SOC for Dynamically High-Risk Multiple Myeloma Study

> **NCT07648459** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 46 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** anti-BCMA/CD3 bispecific antibody

## Key facts

- **NCT ID:** NCT07648459
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2027-07-09
- **Final completion:** 2028-07-30
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2026-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07648459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07648459, "CM336-SOC for Dynamically High-Risk Multiple Myeloma Study". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07648459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*